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The aim of this systematic review and meta-analysis was to analyze the effects of
grape seed extract (GSE) on glycemic control and serum lipoproteins, inflammation
and body weight. Two independent authors systematically searched online databases
including EMBASE, Scopus, PubMed, Cochrane Library, and Web of Science from
inception until May 30, 2019. Cochrane Collaboration risk of bias tool was applied to
assess the methodological quality of included trials. The heterogeneity among the
included studies was assessed using Cochrane's Q test and I-square (I2) statistic. Data
were pooled using a random-effects model and weighted mean difference (WMD)
was considered as the overall effect size. Fifty trials were included in this meta-analy-
sis. Pooling effect sizes from studies demonstrated a significant decrease in fasting
plasma glucose (FPG) (WMD): −2.01; 95% confidence interval (CI): −3.14, −0.86),
total cholesterol (TC; WMD: −6.03; 95% CI: −9.71, −2.35), low-density lipoprotein
(LDL) cholesterol (WMD: −4.97; 95% CI: −8.37, −1.57), triglycerides (WMD: −6.55;
95% CI: −9.28, −3.83), and C-reactive protein (CRP) concentrations (WMD: −0.81;
95% CI: −1.25, −0.38) following GSE therapy. Grape seed did not influence HbA1c,
HDL cholesterol levels, and anthropometric measurements. This meta-analysis dem-
onstrated that GSE intake significantly reduced FPG, TC, LDL cholesterol, triglycer-
ides, and CRP levels.
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1 | INTRODUCTION
Dyslipidemia, particularly elevated plasma low-density lipoprotein
(LDL) cholesterol levels, is the most important risk factor for cardio-
vascular disease (CVD) (Catapano et al., 2016). Apart from smoking
and arterial hypertension, another important risk factors for CVD is
metabolic syndrome (MetS). This syndrome is clustering of metabolic
disorders, including abdominal type of obesity, glucose, hypertension,
intolerance/hyperglycemia, and atherogenic dyslipidemia (decreased
high-density lipoprotein (HDL) cholesterol and increased triglyceride
levels with normal or moderately elevated LDL cholesterol) (Alberti,
Zimmet, & Shaw, 2006; Chapman et al., 2011; Ferrari et al., 2016;
Fruchart et al., 2008; Grundy et al., 2005). LDL particles in athero-
genic dyslipidemia are small and dense and are considered to be more
atherogenic than large buoyant LDL particles (Reiner, 2017). Approxi-
mately, 20–25% of adults in the world, both in developed and
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developing countries are affected by this syndrome which is charac-
terized by abdominal obesity as a phenotypic manifestation. The most
important etiopathogenic mechanism of MetS is insulin resistance
causing mobilization of fatty acids, while other possible mechanisms
include increased biomarkers of oxidative stress and low-grade
chronic inflammation (Cameron, Shaw, & Zimmet, 2004). As a result,
MetS is strongly associated with CVD and Type 2 diabetes mellitus
(T2DM). Therefore, a twofold increase in cardiovascular outcomes
and a 1.5-fold increase in all causes of death as well as an increased
incidence of T2DM are associated with this syndrome (Grundy et al.,
2005; Mottillo et al., 2010). On the other hand, atherogenic dys-
lipidemia is not only predictor of macrovascular atherosclerotic dis-
ease and CVD events but it is also a risk factor for microvascular
disease in T2DM (Sacks et al., 2014). Several studies have shown that
MetS is associated with many other metabolic diseases such as non-
alcoholic fatty liver disease, obstructive sleep apnoea, systemic lupus
erythematosus, polycystic ovary syndrome, and vascular dementia
(Cornier et al., 2008; Mok, Mok, Dixon, Armstrong, & Shaw, 1982;
Uzunlulu, Caklili, & Oguz, 2016).
Grape seed has high flavonoid content. Its beneficial effects on
health have been evaluated in many studies. These studies have
reported that grape seed polyphenols had a beneficial effect on meta-
bolic abnormalities in patients with and without MetS. Some of these
studies have shown that an extract of grape seed, which is rich in
flavanols, has antioxidant properties (Puiggròs et al., 2005), improves
lipoprotein metabolism (Del Bas et al., 2005), restricts adipogenesis
(Pinent et al., 2005), mimics insulin action (Pinent et al., 2004), and
reduces inflammation (Terra et al., 2011). Results of a meta-analysis
published in 2011, in which nine RCTs were included, showed that
grape seed extract (GSE) administration did not have any effect on
total cholesterol (TC), LDL cholesterol, HDL cholesterol, triglycerides
and C-reactive protein (CRP) levels (Feringa, Laskey, Dickson, & Col-
eman, 2011). A study by Argani et al. (2016) showed that taking GSE
for 8 weeks by patients with mild to moderate hyperlipidemia led to a
significant decrease in TC, triglycerides, and LDL cholesterol levels.
However, administration of GSE for 8 weeks in T2DM patients did
not affect serum lipids (Abedini, Pourghassem, Babaei, Aliasgarzadeh,
& Pourabdollahi, 2013).
Since the results of these studies were not conclusive, this meta-
analysis was performed to evaluate the effect of GSE administration
on glycemic control, serum lipoproteins, CRP levels, and obesity as
defined by anthropometric parameters.
2 | MATERIALS AND METHODS
2.1 | Search and studies selection strategies
Scientific international databases, including EMBASE, Cochrane
Library, Web of Science, and PubMed were searched for relevant
studies published from incent until May 30, 2019. A search strat-
egy was developed using the following MeSH and text keywords;
intervention “GSE” OR “grape seed powder (GSE)” OR “GSE
beverages” AND “supplementation” OR “intake” OR “administra-
tion” OR “consumption,” AND outcomes parameters “fasting glu-
cose” OR “fasting plasma glucose (FPG)” OR “HbA1c” OR “TC”
“triglycerides (TG)” OR “LDL cholesterol” OR “LDL-C" OR “HDL
cholesterol” OR “HDL-C" OR “CRP” OR “body weight” OR “body
mass index (BMI).”
2.2 | Inclusion and exclusion criteria
RCTs complying with the following criteria were included in meta-
analysis: human trials with either crossover design or parallel, trials
with data on the effects of GSE on glycemic control, serum lipopro-
teins, CRP and anthropometric measurements (including mean
changes of FPG, HbA1c, serum lipoproteins, CRP, body weight and
BMI with SD and related 95% confidence interval (CI) for the both
intervention and placebo groups). Other studies such as animal experi-
ments, in vitro studies, case reports, observational studies, trials with-
out a control group, and studies that did not achieve the least quality
score were excluded from this meta-analysis.
2.3 | Data extraction and quality assessment
Two independent authors (OA and BN) screened the articles based
on the eligibility criteria. As the first step, the title and abstract of
studies were reviewed. Then, the full text of relevant studies was
assessed to ascertain the suitability of a study for the meta-analy-
sis. Any disagreement was resolved by the judgment of the third
author (Z.A.).
Following data were taken from selected studies: the first
authors' name, study location, year of publication, sample size, age,
study design, dosage of GSE, duration of study, type of disease,
the mean and SD for FPG, HbA1c, serum lipoproteins, CRP, body
weight, and BMI in each intervention group. The quality of the
selected RCTs was independently assessed by the same authors
using the Cochrane Collaboration risk of bias tool based on the
following criteria: “randomization generation, allocation conceal-
ment, blinding of participants and outcome assessors, incomplete
outcome data, and selective outcome reporting, and other sources
of bias.”
2.4 | Data synthesis and statistical analysis
The effects of GSE consumption on the changes of the following
parameters were calculated: (a) FPG, (b) HbA1c, (c) triglycerides, (d)
TC, (e) LDL cholesterol, (f) HDL cholesterol, (g) CRP, (h) body weight,
and (i) BMI. Weighted mean difference (WMD) with 95% CI was used
for pooling data to determine effect sizes. The change score approach
was used to calculate the effect size of GSE intake on the identified
outcome. The random-effect model was used to report the pooled
effect sizes using 95% CI.
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2.5 | Heterogeneity and publication bias
Heterogeneity of included studies was assessed using Cochrane's Q
test (with significant p-value <0.1) and I-square test (I2 greater than
50% showing significant heterogeneity). The funnel plot, as well as
the Begg's and Egger's regression tests was used to determine the
publication bias. Both STATA 11.0 (Stata Corp., College Station, TX)
and Review Manager 5.3 (Cochrane Collaboration, Oxford, UK) were
applied for data analysis.
3 | RESULTS
3.1 | Characteristics of studies
After screening 724 studies, 15 (Abedini et al., 2013; Alirezaei et
al., 2017; Argani et al., 2016; Clifton, 2004; Kar, Laight, Rooprai,
Shaw, & Cummings, 2009; Mellen, Daniel, Brosnihan, Hansen, &
Herrington, 2010; Park, Edirisinghe, Choy, Waterhouse, & Burton-
Freeman, 2016; Pourghassem-Gargari, Abedini, Babaei,
Aliasgarzadeh, & Pourabdollahi, 2011; Sano et al., 2007;
Sivaprakasapillai, Edirisinghe, Randolph, Steinberg, & Kappagoda,
2009; Taghizadeh, Malekian, Memarzadeh, Mohammadi, & Asemi,
2016; Terauchi et al., 2014; Turki et al., 2016; Vigna et al., 2003;
Ward et al., 2005) of them were eligible to be included in this
meta-analysis. These studies were detected by a process that is
shown in Figure 1. General characteristics of eligible studies are
summarized in Table 1. The studies were conducted in Italy (Vigna
et al., 2003), Australia (Clifton, 2004; Ward et al., 2005), Japan
(Sano et al., 2007; Terauchi et al., 2014), United Kingdom (Kar et
al., 2009), United States (Mellen et al., 2010; Park et al., 2016;
Sivaprakasapillai et al., 2009), Iran (Abedini et al., 2013; Alirezaei et
al., 2017; Argani et al., 2016; Pourghassem-Gargari et al., 2011;
Taghizadeh et al., 2016), and Tunisia (Turki et al., 2016). Studies
were published between 2003 and 2017. Ten studies (Abedini et
al., 2013; Argani et al., 2016; Park et al., 2016; Pourghassem-
F IGURE 1 Flowchart of number of studies
identified and included into the meta-analysis
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Gargari et al., 2011; Sano et al., 2007; Sivaprakasapillai et al.,
2009; Taghizadeh et al., 2016; Terauchi et al., 2014; Turki et al.,
2016; Ward et al., 2005) had parallel design and other (Alirezaei et
al., 2017; Clifton, 2004; Kar et al., 2009; Mellen et al., 2010; Vigna
et al., 2003) had crossover design. One study was performed on
men (Vigna et al., 2003), two studies (Taghizadeh et al., 2016;
Terauchi et al., 2014) on women, and other studies (Abedini et al.,
2013; Alirezaei et al., 2017; Argani et al., 2016; Clifton, 2004; Kar
et al., 2009; Mellen et al., 2010; Park et al., 2016; Pourghassem-
Gargari et al., 2011; Sano et al., 2007; Sivaprakasapillai et al.,
2009; Turki et al., 2016; Ward et al., 2005) on both sexes. Totally,
825 subjects (451 in intervention and 374 in control group) were
enrolled in these studies (Abedini et al., 2013; Alirezaei et al.,
2017; Argani et al., 2016; Clifton, 2004; Kar et al., 2009; Mellen et
al., 2010; Park et al., 2016; Pourghassem-Gargari et al., 2011; Sano
et al., 2007; Sivaprakasapillai et al., 2009; Taghizadeh et al., 2016;
Terauchi et al., 2014; Turki et al., 2016; Vigna et al., 2003; Ward
et al., 2005). Mean age of the participants was between 19.8
(Taghizadeh et al., 2016) and 63.6 (Ward et al., 2005) years, and
their mean BMI was between 21.3 ( Terauchi et al., 2014) and 37
(Sivaprakasapillai et al., 2009) kg/m2. Trial duration ranged between
4 (Alirezaei et al., 2017; Clifton, 2004; Kar et al., 2009; Mellen et
al., 2010; Sivaprakasapillai et al., 2009; Vigna et al., 2003) and 25
(Turki et al., 2016) weeks. Dosage of GSE in these studies varied
between 100 ( Terauchi et al., 2014) and 2,000 mg/day (Turki et
al., 2016). Four studies (Sano et al., 2007; Taghizadeh et al., 2016;
Terauchi et al., 2014; Vigna et al., 2003) were made on healthy
subjects, and other studies were performed on subjects with ele-
vated cholesterol (Clifton, 2004), hypertension (Ward et al., 2005),
T2DM (Abedini et al., 2013; Kar et al., 2009; Pourghassem-Gargari
et al., 2011), MetS (Sivaprakasapillai et al., 2009), CVD (Mellen et
al., 2010), hyperlipidemia (Argani et al., 2016), prehypertension
(Park et al., 2016), chronic kidney disease (Turki et al., 2016), and
subjects on hemodialysis (Alirezaei et al., 2017). Studies of Sano et
al. (2007), Sivaprakasapillai et al. (2009), and Terauchi et al. (2014),
each have two effect sizes due to having two intervention groups
with two different doses of supplementation.
3.2 | The effects of GSE on glycemic control
Combining eight effect sizes from seven studies (Abedini et al., 2013;
Mellen et al., 2010; Park et al., 2016; Pourghassem-Gargari et al.,
2011; Sano et al., 2007; Taghizadeh et al., 2016; Turki et al., 2016),
we found a significant decrease in FPG concentrations following GSE
intake (WMD: −2.01; 95% CI: −3.14, −0.87) (Table 2 and Figure 2a).
This finding remained unchanged in some subgroups, except for stud-
ies on subjects with baseline FPG <100 mg/dl (WMD: −1.24; 95% CI:
−5.56, 3.08), trials with duration >6 weeks (WMD: −0.96; 95% CI:
−4.94, 3.02), GSE dosages <300 mg/day (WMD: 1.18; 95% CI: −5.24,
7.62), studies performed on healthy subjects (WMD: −1.24; 95% CI:
−5.56, 3.08), crossover design studies (WMD: −0.10; 95% CI: −7.01,
6.81), and studies performed on individuals with normal BMI (WMD:
−1.24; 95% CI: −5.56, 3.08) (Table 3).
Pooling data from three studies (Abedini et al., 2013;
Pourghassem-Gargari et al., 2011; Sano et al., 2007) with four effect
sizes, no significant effect of GSE on HbA1c levels was found (WMD:
−0.05; 95% CI: −0.21, 0.11) (Table 2 and Figure 2b). Due to the small
number of effect sizes, we did not perform the subgroups analysis.
3.3 | The effects of GSE on serum lipoproteins
The pooled analysis of data from 13 studies (Abedini et al., 2013;
Alirezaei et al., 2017; Argani et al., 2016; Clifton, 2004; Kar et al.,
2009; Mellen et al., 2010; Park et al., 2016; Pourghassem-Gargari et
al., 2011; Sano et al., 2007; Sivaprakasapillai et al., 2009; Taghizadeh
et al., 2016; Turki et al., 2016; Vigna et al., 2003) with 15 effect sizes
showed a significant reduction in TC concentrations after the intake
of GSE (WMD: −6.03; 95% CI: −9.71, −2.35) (Table 2 and Figure 2c).
However, subgroup analysis showed conflicting findings between
studies on subjects with TC levels <200 mg/dl (WMD: −3.78; 95% CI:
−8.72, 1.16), trials with duration ≤6 weeks (WMD: −2.09; 95%
CI: −7.10, 2.90), GSE dosages ≥300 mg/day (WMD: −0.86; 95% CI:
−6.36, 4.63), studies performed on healthy subjects (WMD: −1.94;
95% CI: −10.20, 6.32), crossover design studies (WMD: −0.77; 95%
TABLE 2 The effects of grape seed extract on glycemic control, serum lipids, inflammation, and anthropometric measurements
Variables Number of effect sizes Weighted mean difference CI 95% p-Value
Heterogeneity
I2 (%) p-Value heterogeneity
FPG 8 −2.00 −3.14, −0.86 .001 0.0 .862
HbA1C 4 −0.05 −0.21, 0.11 .545 0.0 .559
TC 15 −6.03 −9.71, −2.35 .001 23.3 .195
LDL-C 13 −4.97 −8.37, −1.56 .004 28.6 .157
TG 15 −6.55 −9.28, −3.83 <.001 34.5 .092
HDL-C 13 −0.71 −1.89, 0.38 .202 21.3 .228
CRP 6 −0.81 −1.25, −0.38 <.001 0.0 .432
Body weight 7 0.41 −1.48, 2.29 .673 0.0 .998
BMI 5 −0.02 −0.95, 0.90 .961 0.0 .982
Abbreviations: BMI, body mass index; CRP, C-reactive protein; FPG, fasting plasma glucose; HbA1C: hemoglobin A1C; HDL-C, high-density lipoprotein
cholesterol; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol; TG, triglycerides.
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CI: −8.31, 6.77), studies made on individuals with normal BMI (WMD:
−3.72; 95% CI: −12.74, 5.29), as well as studies on overweight
(WMD: 3.05; 95% CI: −10.67, 16.78) and obese subjects (WMD:
−4.55; 95% CI: −9.68, 0.57) (Table 3).
GSE administration had significant lowering effect on LDL choles-
terol concentrations according to meta-analysis of 11 studies (Abedini
et al., 2013; Alirezaei et al., 2017; Argani et al., 2016; Clifton, 2004;
Mellen et al., 2010; Park et al., 2016; Pourghassem-Gargari et al.,
2011; Sano et al., 2007; Sivaprakasapillai et al., 2009; Taghizadeh et
al., 2016; Vigna et al., 2003) with 13 effect sizes (WMD: −4.97; 95%
CI: −8.37, −1.56) (Table 2 and Figure 2d). Although this effect was
also found in some subgroup analyses, GSE intake had no significant
effect on LDL cholesterol concentrations in studies on subjects with
LDL cholesterol levels <100 mg/dl (WMD: −5.46; 95% CI: −11.85,
0.92), trials with duration ≤6 weeks (WMD: −2.87; 95% CI: −7.24,
1.48), GSE dosages ≥300 mg/day (WMD: −0.59; 95% CI: −5.26,
4.08), studies performed on healthy subjects (WMD: −2.54; 95% CI:
−9.10, 4.01), crossover design studies (WMD: 1.89; 95% CI: −5.27,
9.06), studies performed on individuals with normal BMI (WMD:
−3.43; 95% CI: −10.41, 3.54) and overweight subjects (WMD: 1.42;
95% CI: −11.27, 14.13) (Table 3).
The combined meta-analysis of 15 effect sizes derived from 13
studies (Abedini et al., 2013; Alirezaei et al., 2017; Argani et al., 2016;
Clifton, 2004; Kar et al., 2009; Mellen et al., 2010; Park et al., 2016;
Pourghassem-Gargari et al., 2011; Sano et al., 2007; Sivaprakasapillai
et al., 2009; Taghizadeh et al., 2016; Turki et al., 2016; Vigna et al.,
2003) demonstrated a significant reduction in triglycerides concentra-
tions following administration of GSE (WMD: −6.55; 95% CI: −9.28,
−3.83) (Table 2 and Figure 2e). This finding did not change in most
subgroups, except for studies on subjects with triglycerides levels
<150 mg/dl (WMD: −5.03; 95% CI: −15.75, 5.68), studies performed
on healthy subjects (WMD: −10.34; 95% CI: −24.03, 3.34), and stud-
ies performed on overweight (WMD: 10.52; 95% CI: −15.64, 36.68)
and obese subjects (WMD: −0.74; 95% CI: −9.84, 8.35) (Table 3).
F IGURE 2 (a–j) Meta-analysis
metabolic profiles and anthropometric
measurements weighted mean difference
estimates for (a) FPG, (b) HbA1c, (c) TC,
(d) LDL cholesterol, (e) triglycerides, (f)
HDL cholesterol, (g) CRP, (h) body weight,
and (j) BMI in the GSE and placebo groups
(CI = 95%)
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When we combined data from 11 studies (Abedini et al., 2013;
Alirezaei et al., 2017; Argani et al., 2016; Clifton, 2004; Kar et al.,
2009; Mellen et al., 2010; Park et al., 2016; Sano et al., 2007;
Sivaprakasapillai et al., 2009; Taghizadeh et al., 2016; Vigna et al.,
2003) consisting of 13 effect sizes, no significant effect was found on
HDL cholesterol levels after the intake of GSE (WMD: −0.71; 95% CI:
−1.80, 0.38) (Table 2 and Figure 2f). The same finding was also seen
in all subgroups (Table 3).
3.4 | The effects of GSE on CRP levels
The pooled analysis of data from six studies (Alirezaei et al., 2017;
Clifton, 2004; Kar et al., 2009; Mellen et al., 2010; Turki et al., 2016;
Ward et al., 2005) showed a significant reduction CRP concentrations
after the intake of GSE (WMD: −0.81; 95% CI: −1.25, −0.38) (Table 2
and Figure 2g). Due to the limited number of available studies, we
were unable to perform any subgroup analysis.
3.5 | The effects of GSE on anthropometric
measurements
Our meta-analysis on five studies (Abedini et al., 2013;
Pourghassem-Gargari et al., 2011; Sano et al., 2007; Taghizadeh et
al., 2016; Terauchi et al., 2014) with 7 effect sizes, showed no sig-
nificant effect on body weight after the treatment with GSE
(WMD: 0.41; 95% CI: −1.48, 2.29) (Table 2 and Figure 2h), Due to
only few available data, analysis of subgroups was not performed.
(Table 3).
F IGURE 2 (Continued)
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GSE supplementation had no significant effect on BMI according
to meta-analysis of 4 studies (Abedini et al., 2013; Pourghassem-
Gargari et al., 2011; Sano et al., 2007; Taghizadeh et al., 2016) five
effect sizes (WMD: −0.02; 95% CI: −0.95, 0.90) (Table 2 & Figure 2j).
Available data were not enough to perform the analysis of subgroups.
4 | DISCUSSION
The current meta-analysis showed that GSE intake significantly
reduced FPG, TC, LDL cholesterol, triglycerides, and CRP levels, but
did not affect HbA1c, HDL cholesterol levels, and anthropometric
measurements.
4.1 | Effects on glycemic control and serum
lipoproteins
We found that GSE intake significantly reduced FPG, TC, LDL choles-
terol, and triglycerides levels, but did not have any significant effect
on HbA1c and HDL cholesterol levels. In animal models, it was
F IGURE 2 (Continued)
8 ASBAGHI ET AL.
reported that dietary grape seed intake significantly increased fecal
excretion of cholesterol by approximately twofold and these animals
had lower TC, LDL cholesterol, VLDL cholesterol, triglycerides and
higher HDL cholesterol (Tebib, Besancon, & Rouanet, 1994). In a
meta-analysis by Feringa et al. (2011), which included results of nine
RCTs, no significant effect of grape seed on serum TC, LDL choles-
terol, HDL cholesterol, triglycerides, and diastolic blood pressure
could be shown. Grape seed administration at a dosage of 200 mg/
day to patients with mild hyperlipidemia during 8 weeks decreased
TC, LDL cholesterol, and oxidized LDL cholesterol (Razavi et al.,
2013). In another study on hypercholesterolemic patients, combined
administration of niacin-bound chromium and GSE for 2 months sig-
nificantly decreased TC and LDL cholesterol levels while HDL choles-
terol did not change (Preuss et al., 2000). The administration of grape
seed at a dosage of 300 mg twice a day to female volleyball players
for 8 weeks had no significant effects on FPG and serum lipids
(Taghizadeh et al., 2016). Earlier studies have shown that phenolic
compounds in grape seed may improve FPG and insulin function by
increasing expression and plasma adiponectin concentrations (Maeda
et al., 2001; Olholm, Paulsen, Cullberg, Richelsen, & Pedersen, 2010).
F IGURE 2 (Continued)
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Enhanced expression of insulin signaling pathway-related proteins,
including Akt and glucose transporter Type 4, mRNA expression of
adiponectin, adiponectin receptor R1, and AMP-activated protein
kinase-α together with increased mRNA levels of glycogen synthase
and suppressed mRNA expression of. These mechanisms may explain
beneficial effects of grape seed on FPG and serum lipids (Meeprom,
Sompong, Suwannaphet, Yibchok-anun, & Adisakwattana, 2011). In
addition, it seems the beneficial effects of grape seed on TC and LDL
cholesterol levels may be due to inhibiting intestinal cholesterol
absorption. However, it is most likely that the primary beneficial
effect of grape seed occurs due to mechanisms other than just
decrease of plasma lipoproteins concentrations, including scavenging
of hydroxyl and peroxyl radicals, antioxidant activities, and
suppressing of the oxidation of LDL. Therefore, it seems that the
antioxidant properties of grape seed polyphenols are central to their
mechanism(s) of action, which also include cellular signaling mecha-
nisms and interactions at the genomic level (Leifert & Abeywardena,
2008).
4.2 | Effects on inflammatory markers and
anthropometric measurements
This meta-analysis showed that GSE intake significantly reduced CRP
levels, but did not influence anthropometric measurements, that is,
obesity. It has been reported that grape seed has anti-inflammatory
and antioxidative properties. in vitro studies demonstrated that flavo-
noid-rich food products suppress lipoxygenase pathways, which
F IGURE 2 (Continued)
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TABLE 3 Subgroup analyses of grape seed extract on FPG and lipid profiles
NO WMD (95% CI) p Within group p Heterogeneity I2 (%) Between-study I2 (%)
Subgroup analyses of GSE supplementation on FPG levels
Baseline serum FPG (mg/dl)
<100 3 −1.24 (−5.56, 3.08) .573 .582 0.0 0.719
>100 5 −2.06 (−3.24, −0.88) .001 .731 0.0
Trial duration (week)
≤6 2 −2.09 (−3.28, −0.91) .001 .565 0.0 0.592
>6 6 −0.96 (−4.94, 3.02) .636 .759 0.0
GSE dosage
≥300 5 −2.10 (−3.26, −0.95) <.001 .826 0.0 0.323
<300 3 1.18 (−5.24, 7.62) .718 .684 0.0
Health status
Healthy 3 −1.24 (−5.56, 3.08) .573 .582 0.0 0.719
Unhealthy 5 −2.06 (−3.24, −0.88) .001 .731 0.0
Study design
Crossover 1 −0.10 (−7.01, 6.81) .977 — — 0.584
Parallel 7 −2.05 (−3.21, −0.90) <.001 .817 0.0
BMI
Normal 3 −1.24 (−5.56, 3.08) .573 .582 0.0 0.895
Obese 3 −2.09 (−3.30, −0.89) .001 .472 0.0
Subgroup analyses of GSE supplementation on TC levels
Baseline serum TC (mg/dl)
<200 9 −3.78 (−8.72, 1.16) .134 .966 0.0 0.182
>200 6 −8.82 (−14.33, −3.31) .002 .015 64.5
Trial duration (week)
≤6 8 −2.09 (−7.10, 2.90) .411 .912 0.0 0.023
>6 7 −10.64 (−16.07, −5.22) <.001 .108 42.4
GSE dosage
≥300 9 −0.86 (−6.36, 4.63) .758 .973 0.0 0.013
<300 6 −10.21 (−15.16, −5.26) <.001 .078 49.5
Health status
Healthy 4 −1.94 (−10.20, 6.32) .645 .698 0.0 0.278
Unhealthy 11 −7.04 (−11.15, −2.93) .001 .110 36.1
Study design
Crossover 5 −0.77 (−8.31, 6.77) .841 .918 0.0 0.118
Parallel 10 −7.67 (−11.88, −3.46) <.001 .095 39.4
BMI
Normal 3 −3.72 (−12.74, 5.29) .418 .779 0.0 0.114
Overweight 2 3.05 (−10.67, 16.78) .663 .583 0.0
Obese 6 −4.55 (−9.68, 0.57) .082 .839 0.0
Subgroup analyses of GSE supplementation on LDL-C levels
Baseline serum LDL-C (mg/dl)
<100 4 −5.46 (−11.85, 0.92) .094 .607 0.0 0.857
>100 9 −4.77 (−8.79, −0.74) .020 .060 46.4
Trial duration (week)
≤6 7 −2.87 (−7.24, 1.48) .196 .323 14.0 0.133
>6 6 −8.22 (−13.66, −2.77) .003 .181 34.0
(Continues)
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TABLE 3 (Continued)
NO WMD (95% CI) p Within group p Heterogeneity I2 (%) Between-study I2 (%)
GSE dosage
≥300 7 −0.59 (−5.26, 4.08) .805 .867 0.0 0.007
<300 6 −9.91 (−14.88, −4.94) <.001 .212 29.7
Health status
Healthy 4 −2.54 (−9.10, 4.01) .448 .809 0.0 0.396
Unhealthy 9 −5.86 (−9.84, −1.87) .004 .057 47.1
Study design
Crossover 4 1.89 (−5.27, 9.06) .604 .926 0.0 0.033
Parallel 9 −6.97 (−10.84, −3.09) <.001 .161 32.1
BMI
Normal 3 −3.43 (−10.41, 3.54) .334 .809 0.0 0.632
Overweight 2 1.42 (−11.27, 14.13) .826 .701 0.0
Obese 5 −6.81 (−11.69, −1.94) .006 .337 12.0
Subgroup analyses of GSE supplementation on TG levels
Baseline serum TG (mg/dl)
<150 6 −5.03 (−15.75, 5.68) .358 .149 38.5 0.773
>150 9 −6.66 (−9.48, −3.83) <.001 .106 39.3
Trial duration (week)
≤6 8 −5.54 (−8.38, −2.69) <.001 .415 1.9 0.014
>6 7 −18.15 (−27.78, −8.52) <.001 .224 26.8
GSE dosage
≥300 9 −6.10 (−8.95, −3.26) <.001 .369 8.0 0.280
<300 6 −11.61 (−21.17, −2.04) .017 .042 56.6
Health status
Healthy 4 −10.34 (−24.03, 3.34) .139 .247 27.6 0.579
Unhealthy 11 −6.39 (−9.18, −3.61) <.001 .076 40.9
Study design
Crossover 5 −6.01 (−8.97, −3.05) <.001 .416 0.0 0.361
Parallel 10 −9.56 (−16.58, −2.55) .008 .055 45.9
BMI
Normal 3 −15.87 (−30.60, −1.14) .035 .922 0.0 0.184
Overweight 2 10.52 (−15.64, 36.68) .431 .289 11.1
Obese 6 −0.74 (−9.84, 8.35) .873 .328 13.5
Subgroup analyses of GSE supplementation on HDL-C levels
Baseline serum HDL-C (mg/dl)
<50 9 −0.56 (−1.76, 0.64) .362 .079 43.3 0.568
>50 4 −1.38 (−3.94, 1.17) .289 .847 0.0
Trial duration (week)
≤6 8 −0.15 (−1.52, 1.21) .821 .156 34.1 0.194
>6 5 −1.65 (−3.45, 0.14) .071 .568 0.0
GSE dosage
≥300 8 0.07 (−1.45, 1.60) .926 .157 34.0 0.155
<300 5 −1.50 (−3.05, 0.04) .056 .624 0.0
Health status
Healthy 4 −1.39 (−4.96, 2.17) .444 .812 0.0 0.693
Unhealthy 9 −0.63 (−1.78, 0.50) .274 .078 43.4
(Continues)
12 ASBAGHI ET AL.
increase pro-inflammatory leukotrienes (Schewe, Kuhn, & Sies, 2002).
It has also been suggested that orally ingested GSE helps preventing
imbalanced cytokine patterns (Terra et al., 2011). In a study by
Irandoost, Ebrahimi-Mameghani, and Pirouzpanah (2013), grape seed
consumption improved insulin resistance and inflammatory markers in
overweight/obese women. Supplementation with 2 g/day grape seed
during 6 months in patients with chronic kidney disease improved kid-
ney function by its anti-inflammatory and antioxidant properties (Turki
et al., 2016). Administration of 200 or 400 mg/day grape seed to
healthy subjects during 8 and 12 weeks failed to show any significant
effect on body weight and BMI (Sano et al., 2007). In another study,
supplementation neither with low dose (100 mg/day) nor with high
dose (200 mg/day) of grape seed to middle-aged women during
8 weeks did have any effect on body weight and BMI (Terauchi et al.,
2014). The discrepancies between different studies might be
explained by the different dosages of grape seed used, different dura-
tions of intervention, quality grape seed used, or the different charac-
teristics of study participants. Polyphenols in GSE could be
responsible for its anti-inflammatory effects in experimental studies.
CRP is an acute-phase protein produced by the liver as a response to
tissue damage or inflammation. Therefore, CRP can be used as a
marker of acute inflammation, but it is also used to predict atheroscle-
rotic cardiovascular events since atherosclerosis is characterized by a
low-grade chronic inflammation (Danesh et al., 2004). Our finding that
GSE reduces CRP levels might be an interesting additional explanation
why GSE could have antiatherogenic effects. It is in accordance with
findings of some other authors who have suggested that grape seed
has anti-inflammatory effects.
5 | CONCLUSIONS
This meta-analysis demonstrated that GSE intake significantly reduced
FPG, TC, LDL cholesterol, triglycerides, and CRP levels, but did not
affect HbA1c, HDL cholesterol levels, and anthropometric
measurements.
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